Drug Profile
Letrozole - Novartis
Alternative Names: CGP 20267; CGS 20267; FemaraLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Novartis
- Developer Eli Lilly and Company; Gynecologic Oncology Group; M. D. Anderson Cancer Center; National Cancer Institute (USA); Novartis; SOLTI Breast Cancer Research Group; University of Colorado at Denver
- Class Antineoplastics; Infertility therapies; Nitriles; Small molecules; Triazoles
- Mechanism of Action Aromatase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Breast cancer
- Phase III HER2 negative breast cancer
- Phase II Endometrial cancer; Fallopian tube cancer; Leiomyosarcoma; Ovarian cancer; Peritoneal cancer
- Discontinued Delayed puberty; Endometriosis; Female infertility
Most Recent Events
- 10 May 2023 Novartis Pharmaceuticals completes a phase II RIGHT Choice trial for Breast cancer (Combination therapy, Late-stage disease, Metastatic disease, Inoperable/Unresectable) in Egypt, India, Jordan, Lebanon, Russian Federation, Saudi Arabia, Singapore, South Africa, Thailand, Turkey, Taiwan, Malaysia, Vietnam(PO) (NCT03839823)
- 28 Mar 2023 Efficacy data from a phase II trial in Fallopian tube cancer released by Mount Sinai Medical Center
- 28 Mar 2023 Mount Sinai Medical Center plans a head-to-head study of ribociclib and letrozole vs the best current therapies